Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) have been given an average rating of “Hold” by the thirteen research firms that are currently covering the company, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $24.67.
Several research firms have weighed in on RAPT. JPMorgan Chase & Co. lowered their price target on RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Guggenheim lowered RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Barclays lowered RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $13.00 to $4.00 in a report on Friday, May 10th. Finally, Wolfe Research reissued a “peer perform” rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th.
Get Our Latest Report on RAPT Therapeutics
Institutional Inflows and Outflows
RAPT Therapeutics Stock Down 3.1 %
NASDAQ:RAPT opened at $3.64 on Friday. The firm has a market capitalization of $126.86 million, a price-to-earnings ratio of -1.18 and a beta of 0.36. RAPT Therapeutics has a twelve month low of $2.61 and a twelve month high of $27.35. The stock’s 50 day moving average price is $3.65 and its two-hundred day moving average price is $10.88.
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, analysts anticipate that RAPT Therapeutics will post -2.93 earnings per share for the current year.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Further Reading
- Five stocks we like better than RAPT Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Business Services Stocks Investing
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- About the Markup Calculator
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.